echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Xi'an Yangsen Gussechi Yusazumap injection was approved in China.

    Xi'an Yangsen Gussechi Yusazumap injection was approved in China.

    • Last Update: 2020-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Gusageu sepsis injection is the world's first monoclonal anti-human leukocyte interleukin-23 (IL-23) approved for psoriasis treatment, which destroys the iLE-23 medial conduction, activation and procastod reaction of cytokines by blocking psoriasis by blocking IL-23 binding to cell surface IL-23 receptors.
    the approved Gussage Yu sing-in injection was declared by Janssen-Cilag International NV, agent of Xi'an Jansen-Cilag Pharmaceutical Co., Ltd., which was included in the list of the country's first batch of clinically urgently needed new drugs.
    the State Drug Administration has accelerated the approval of the listing of the variety in accordance with the procedure sifted at the priority review and approval process.
    So far, the State Drug Administration has approved 25 imports of drugs listed for clinically urgent overseas drugs.
    Source: State Drug Administration.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.